Nanostars amplify ability to image cancer.

abstract：:The investigational menin-MLL inhibitor KO-539 may be active in patients with acute myeloid leukemia: In a phase I trial, the agent induced complete remissions in two patients with relapsed/refractory disease and showed signs of activity in several others. ...

journal_title：Cancer discovery

authors：

更新日期：2020-12-30 00:00:00

abstract：:The FDA authorized 23andMe to market the first direct-to-consumer test to check for three BRCA1/2 mutations associated with a higher risk of developing breast, ovarian, and prostate cancers. The mutations are most commonly found in about 2% of women of Ashkenazi Jewish descent. ...

journal_title：Cancer discovery

authors：

更新日期：2018-05-01 00:00:00

abstract：:The IPRES signature is related to anti-PD-1 response, and high mutational load predicts survival. ...

journal_title：Cancer discovery

authors：

更新日期：2016-05-01 00:00:00

abstract：:Venetoclax-based therapy can induce responses in approximately 70% of older previously untreated patients with acute myeloid leukemia (AML). However, up-front resistance as well as relapse following initial response demonstrates the need for a deeper understanding of resistance mechanisms. In the present study, we rep...

journal_title：Cancer discovery

authors： Pei S,Pollyea DA,Gustafson A,Stevens BM,Minhajuddin M,Fu R,Riemondy KA,Gillen AE,Sheridan RM,Kim J,Costello JC,Amaya ML,Inguva A,Winters A,Ye H,Krug A,Jones CL,Adane B,Khan N,Ponder J,Schowinsky J,Abbott D,Ham

更新日期：2020-04-01 00:00:00

abstract：:An international team of researchers has uncovered multiple new germline mutations that may influence the development of sarcomas. Notably, they found that variants in several DNA damage sensing and repair genes contribute greatly to sarcoma risk, including BRCA2, ATM, ATR, and ERCC2. ...

journal_title：Cancer discovery

authors：

更新日期：2016-10-01 00:00:00

abstract：:Researchers identified a small molecule that stimulates the production of stem cells in umbilical cord blood, potentially expanding treatment options for adults with hematologic cancers. ...

journal_title：Cancer discovery

authors：

更新日期：2014-12-01 00:00:00

abstract：:The EGFR inhibitor osimertinib may be an effective therapy for patients with untreated non-small cell lung cancer who have brain metastases. In a recent study, the drug extended median progression-free survival and increased objective response rates compared with the first-generation EGFR inhibitors gefitinib and erlo...

journal_title：Cancer discovery

authors：

更新日期：2018-11-01 00:00:00

abstract：:Unconventional T-lymphocyte populations are emerging as important regulators of tumor immunity. Despite this, the role of TCRαβ+CD4-CD8-NK1.1- innate αβ T cells (iαβT) in pancreatic ductal adenocarcinoma (PDA) has not been explored. We found that iαβTs represent ∼10% of T lymphocytes infiltrating PDA in mice and human...

journal_title：Cancer discovery

authors： Hundeyin M,Kurz E,Mishra A,Rossi JAK,Liudahl SM,Leis KR,Mehrotra H,Kim M,Torres LE,Ogunsakin A,Link J,Sears RC,Sivagnanam S,Goecks J,Islam KMS,Dolgalev I,Savadkar S,Wang W,Aykut B,Leinwand J,Diskin B,Adam S,Is

更新日期：2019-09-01 00:00:00

abstract：:Findings from a phase I study suggest that delivering high concentrations of the chemotherapy 5-FU directly to brain tumors via the retroviral vector vocimagene amiretrorepvec, or Toca 511, may benefit patients with recurrent high-grade glioma. This investigational treatment was well tolerated and induced robust, dura...

journal_title：Cancer discovery

authors：

更新日期：2018-01-01 00:00:00

abstract：:A report from the American Cancer Society reveals that colorectal cancer in people younger than 50 continues to increase, a trend that has spread to the 50-to-64 age group for the first time. Multiple lines of evidence indicate that obesity, often pinpointed as the cause, is not the only contributor. ...

journal_title：Cancer discovery

authors：

更新日期：2020-06-01 00:00:00

abstract：:Ceritinib and other second-generation inhibitors have demonstrated promising anticancer activity in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Specifically, they can overcome resistance due to certain gatekeeper mutations acquired following crizotinib exposure. These agents now provi...

journal_title：Cancer discovery

authors： Ramalingam SS,Khuri FR

更新日期：2014-06-01 00:00:00

abstract：:According to results from ENZAMET, a global phase III trial, adding enzalutamide to standard treatment for men with metastatic hormone-sensitive prostate cancer is superior in prolonging survival compared with older nonsteroidal antiandrogen drugs. ...

journal_title：Cancer discovery

authors：

更新日期：2019-08-01 00:00:00

abstract：:Sen and colleagues have shown for the first time the clinical application of an oligonucleotide decoy targeting the oncogenic transcription factor STAT3 for the treatment of head and neck tumors. Intratumoral injection of decoy effectively reduced the activity of STAT3 as evidenced by a decrease in several of its tran...

journal_title：Cancer discovery

authors： Koppikar P,Bromberg J

更新日期：2012-08-01 00:00:00

abstract：:Asparagine promotes the survival of cancer cells in response to glutamine withdrawal. ...

journal_title：Cancer discovery

authors：

更新日期：2014-11-01 00:00:00

abstract：:The TIGIT inhibitor tiragolumab, alone or in combination with the PD-L1 inhibitor atezolizumab, may be effective against solid cancers. In phase I and II trials, the agent achieved statistically significant results in multiple solid malignancies-most notably non-small cell lung cancer. ...

journal_title：Cancer discovery

authors：

更新日期：2020-08-01 00:00:00

abstract：:Presenting data on 50 of 55 patients with advanced TRK fusion-positive tumors, researchers reported that 76% of patients responded to the selective pan-TRK inhibitor larotrectinib, and 12% of patients experienced complete responses; 93% of responders remain on therapy. The targeted therapy was well tolerated, with jus...

journal_title：Cancer discovery

authors：

更新日期：2017-08-01 00:00:00

abstract：UNLABELLED:Despite evidence implicating transcription factors, including STAT3, in oncogenesis, these proteins have been regarded as "undruggable." We developed a decoy targeting STAT3 and conducted a phase 0 trial. Expression levels of STAT3 target genes were decreased in head and neck cancers following injection with...

journal_title：Cancer discovery

authors： Sen M,Thomas SM,Kim S,Yeh JI,Ferris RL,Johnson JT,Duvvuri U,Lee J,Sahu N,Joyce S,Freilino ML,Shi H,Li C,Ly D,Rapireddy S,Etter JP,Li PK,Wang L,Chiosea S,Seethala RR,Gooding WE,Chen X,Kaminski N,Pandit K,Jo

更新日期：2012-08-01 00:00:00

abstract：:Notch activation, which is associated with basal-like breast cancer (BLBC), normally directs tissue patterning, suggesting that it may shape the tumor microenvironment. Here, we show that Notch in tumor cells regulates the expression of two powerful proinflammatory cytokines, IL1β and CCL2, and the recruitment of tumo...

journal_title：Cancer discovery

authors： Shen Q,Cohen B,Zheng W,Rahbar R,Martin B,Murakami K,Lamorte S,Thompson P,Berman H,Zúñiga-Pflücker JC,Ohashi PS,Reedijk M

更新日期：2017-11-01 00:00:00

abstract：:Effective targeted therapeutics for squamous cell carcinoma (SCC) are lacking. Here, we uncover Mcl-1 as a dominant and tissue-specific survival factor in SCC, providing a roadmap for a new therapeutic approach. Treatment with the histone deacetylase (HDAC) inhibitor vorinostat regulates Bcl-2 family member expression...

journal_title：Cancer discovery

authors： He L,Torres-Lockhart K,Forster N,Ramakrishnan S,Greninger P,Garnett MJ,McDermott U,Rothenberg SM,Benes CH,Ellisen LW

更新日期：2013-03-01 00:00:00

abstract：:Activating mutations in the EGF receptor (EGFR) are associated with clinical responsiveness to EGFR tyrosine kinase inhibitors (TKI), such as erlotinib and gefitinib. However, resistance eventually arises, often due to a second EGFR mutation, most commonly T790M. Through a genome-wide siRNA screen in a human lung canc...

journal_title：Cancer discovery

authors： de Bruin EC,Cowell C,Warne PH,Jiang M,Saunders RE,Melnick MA,Gettinger S,Walther Z,Wurtz A,Heynen GJ,Heideman DA,Gómez-Román J,García-Castaño A,Gong Y,Ladanyi M,Varmus H,Bernards R,Smit EF,Politi K,Downward J

更新日期：2014-05-01 00:00:00

abstract：:Lung mesenchymal cells promoted neutrophil lipid storage; lipids were transferred to tumor cells. ...

journal_title：Cancer discovery

authors：

更新日期：2020-12-01 00:00:00

abstract：:In a phase I trial, the DARPin MG0250 had an expected safety profile and early signs of efficacy. ...

journal_title：Cancer discovery

authors：

更新日期：2021-01-08 00:00:00

abstract：:The structure of CD20 with the antibody drug rituximab showed the binding mode and 2:2 stoichiometry. ...

journal_title：Cancer discovery

authors：

更新日期：2020-04-01 00:00:00

abstract：UNLABELLED:Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer that most commonly evolves from preexisting prostate adenocarcinoma (PCA). Using Next Generation RNA-sequencing and oligonucleotide arrays, we profiled 7 NEPC, 30 PCA, and 5 benign prostate tissue (BEN), and validated findings ...

journal_title：Cancer discovery

authors： Beltran H,Rickman DS,Park K,Chae SS,Sboner A,MacDonald TY,Wang Y,Sheikh KL,Terry S,Tagawa ST,Dhir R,Nelson JB,de la Taille A,Allory Y,Gerstein MB,Perner S,Pienta KJ,Chinnaiyan AM,Wang Y,Collins CC,Gleave ME,Demi

更新日期：2011-11-01 00:00:00

abstract：UNLABELLED:Epithelial ovarian cancer is the leading cause of death from gynecologic malignancy, and its molecular basis is poorly understood. We previously demonstrated that opioid binding protein cell adhesion molecule (OPCML) was frequently epigenetically inactivated in epithelial ovarian cancers, with tumor suppress...

journal_title：Cancer discovery

authors： McKie AB,Vaughan S,Zanini E,Okon IS,Louis L,de Sousa C,Greene MI,Wang Q,Agarwal R,Shaposhnikov D,Wong JL,Gungor H,Janczar S,El-Bahrawy M,Lam EW,Chayen NE,Gabra H

更新日期：2012-02-01 00:00:00

abstract：: In this issue Grommes and colleagues elegantly show that the irreversible inhibitor of Bruton tyrosine kinase, ibrutinib, promotes a high proportion of durable responses in primary central nervous system lymphoma, a type of diffuse large B-cell lymphoma (DLBCL), and also in secondary DLBCL relapsing to the centra...